Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has provided an update.
Recce Pharmaceuticals reported a change in the securities held by director James Graham, following the expiry and lapse of 2,250,000 unlisted options exercisable at $1.56 on 22 February 2026. After the change, Graham retains 3,000,000 unlisted options exercisable at $0.80 expiring in November 2029, along with 6,801,076 fully paid ordinary shares held indirectly, indicating no new issuance or disposal of shares but a routine options expiry affecting his potential equity exposure.
The adjustment in Graham’s holdings reflects scheduled option expirations rather than an active trading decision or strategic shift in ownership. For stakeholders, the notice signals a modest reduction in the director’s potential future option-derived stake, while confirming stable underlying shareholdings and no immediate capital structure impact for the company.
The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is an Australian biotechnology company focused on developing anti-infective therapies. Its primary assets include proprietary synthetic antibiotics targeted at treating serious and resistant infections, positioning the company within the pharmaceutical and life sciences sector.
Average Trading Volume: 138,062
Technical Sentiment Signal: Buy
Current Market Cap: A$169.2M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.